🇺🇸 FDA
Patent

US 10053514

Human bispecific EGFRvIII and CD3 antibody engaging molecules

granted A61KA61K2039/505A61P

Quick answer

US patent 10053514 (Human bispecific EGFRvIII and CD3 antibody engaging molecules) held by The United States of America as Represented by the Secretary of Health and Human Services, National Institutes of Health expires Mon Aug 16 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as Represented by the Secretary of Health and Human Services, National Institutes of Health
Grant date
Tue Aug 21 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 16 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K2039/505, A61P, A61P35/00